Skip to content

Outcomes of Radiotherapy and Chemotherapy in operated patients of Carcinoma Cervix with residual or recurrent disease

Outcomes of Salvage Chemoradiotherapy followed by brachytherapy in carcinoma cervix patients following inadequate hysterectomy with residual or recurrent disease in a tertiary care oncology centre (SCORE Study) - SCORE study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/093607
Enrollment
100
Registered
2025-08-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Homi Bhabha Cancer Hospital & Mahamana Pandit Madan Mohan Malaviya Cancer Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Carcinoma of Cervix Uteri with residual and/or recurrent disease following inappropriate surgery. - Histopathological proof of Squamous cell carcinoma, adenocarcinoma or adeno-squamous carcinoma - Patients being treated with curative intent using concurrent chemo-radiotherapy (CTRT) followed by brachytherapy. - ECOG PS 1-2 - Patient consenting for participation in study (Written informed consent for prospective patients, Telephonic informed consent for retrospective patients)

Exclusion criteria

Exclusion criteria: - Presence of distant metastases. - Medical condition precluding curative intent treatment for the patient. - History of previous treatment for the present condition. - Patients with immunocompromised states and psychological illness. - Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Disease free survival (DFS)Timepoint: 1 Year

Secondary

MeasureTime frame
Acute and Late treatment toxicities based on CTCAE v5.0 toxicity criteriaTimepoint: 1 Year;Overall Survival (OS)Timepoint: 1 Year;Radiological response as per RECIST V1.1Timepoint: 6 months;Pattern of FailureTimepoint: 1 year

Countries

India

Contacts

Public ContactDr SATYAJIT PRADHAN

Mahamana Pandit Madan Mohan Malaviya Cancer Centre Unit of Tata Memorial Centre

Satyajit.pr@gmail.com9415228261

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026